References
- Goldman J M. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828–2837
- White D L, Saunders V A, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007; 110: 4064–4072
- Shu Y, Leabman M K, Feng B, Mangravite L M, Huang C C, Stryke D, et al. Evolutionary conservation predicts function of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA 2003; 100: 5902–5907
- Gabert J, Beillard E, van der Velden V HJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against cancer program. Leukemia 2003; 17: 2318–2357